<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GRANISETRON</span><br/>(gran'i-se-tron)<br/><span class="topboxtradename">Kytril<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span>; <span class="classification">5-ht<sub>3</sub> antagonist</span><br/><b>Prototype: </b>Ondansetron<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg tablets; 1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Granisetron is a selective serotonin (5-HT<sub>3</sub>) receptor antagonist. Serotonin receptors of the 5-HT<sub>3</sub> type are located centrally in the chemoreceptor trigger zone, and peripherally on the vagal nerve terminals. Serotonin is
         released from the wall of the small intestine, stimulates the vagal afferent neurons through the serotonin (5-HT<sub>3</sub>) receptors, and initiates the vomiting reflex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>This selective serotonin (5-HT<sub>3</sub>) receptor antagonist is used for the prevention of nausea and vomiting associated with cancer chemotherapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose
         cisplatin.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to granisetron.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver disease, pregnancy (category B), lactation, children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nausea and Vomiting</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> &gt;2 y, 10 mcg/kg infused over 30 sec5 min, beginning at least 30 min before initiation of chemotherapy (up to 40 mcg/kg
               per dose has been used) <span class="rdroute">PO</span> 1 mg b.i.d., start 1 mg up to 1 h prior to chemotherapy, then second tab 12 h later or 2 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give only on the day of chemotherapy.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span> Dilute in NS or D5W to a total volume of 2050 mL. Prepare infusion at time of administration; do not mix in solution
                  with other drugs.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 30 sec.  <span class="methodtype">IV Infusion:</span> Infuse diluted drug over 5 min or longer; complete infusion 2030 min prior to initiation of chemotherapy.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) for 24 h after dilution under normal lighting conditions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, somnolence, insomnia, labile mood, anxiety, fatigue. <span class="typehead">GI:</span> Constipation, diarrhea, elevated liver function tests. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> Several minutes. <span class="typehead">Duration:</span> Approximately 24 h. <span class="typehead">Distribution:</span> Widely distributed in body tissues. <span class="typehead">Metabolism:</span> Appears to be metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine as metabolites. <span class="typehead">Half-Life:</span> 1011 h in cancer patients, 45 h in healthy volunteers. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor the frequency and severity of nausea and vomiting.</li>
<li>Lab tests: Monitor liver function; elevated AST and ALT values usually normalize within 2 wk of last dose.</li>
<li>Assess for headache, which usually responds to nonnarcotic analgesics.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Headache requiring an analgesic for relief is a common adverse effect.
            						
         </li>
<li>Learn ways to manage constipation.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>